MARKET

RAPP

RAPP

Rapport Therapeutics Inc
NASDAQ
47.79
-1.03
-2.10%
Opening 10:27 08/12 EDT
OPEN
49.00
PREV CLOSE
48.82
HIGH
49.50
LOW
47.02
VOLUME
49.73K
TURNOVER
--
52 WEEK HIGH
49.50
52 WEEK LOW
13.86
MARKET CAP
2.29B
P/E (TTM)
-15.7207
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RAPP last week (0803-0807)?
Weekly Report · 2d ago
Analysts Offer Insights on NA Companies: Starz Entertainment Corp (STRZ), Bluelinx Holdings (BXC) and Rapport Therapeutics, Inc. (RAPP)
TipRanks · 6d ago
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and Honeywell Aerospace (HONA)
TipRanks · 6d ago
Truist Financial Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)
TipRanks · 6d ago
Myles Minter Initiates Buy on Rapport Therapeutics, Citing De-Risked RAP-219 Epilepsy Program and Multi-Billion-Dollar Peak Sales Potential
TipRanks · 6d ago
Rapport Therapeutics Price Target Maintained With a $65.00/Share by BTIG
Dow Jones · 6d ago
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
Benzinga · 6d ago
Rapport Therapeutics reports Q2 results
Seeking Alpha · 6d ago
More
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.

Webull offers Rapport Therapeutics Inc stock information, including NASDAQ: RAPP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPP stock methods without spending real money on the virtual paper trading platform.